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The aryl hydrocarbon receptor (AHR) is a ligand-activated transcription factor initially iden-
tified because of its role in controlling the cellular response to environmental molecules.
More recently, AHR has been shown to play a crucial role in controlling innate and adaptive
immune responses through several mechanisms, one of which is the regulation of tryp-
tophan metabolism. Indoleamine-2,3-dioxygenase (IDO) and tryptophan-2,3-dioxygenase
(TDO) are considered rate-limiting enzymes in the tryptophan catabolism and play important
roles in the regulation of the immunity. Moreover, AHR and IDO/TDO are closely intercon-
nected: AHR regulates IDO and TDO expression, and kynurenine produced by IDO/TDO
is an AHR agonist. In this review, we propose to examine the relationship between AHR
and IDO/TDO and its relevance for the regulation of the immune response in health and
disease.
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AHR SIGNALING PATHWAYS
Aryl hydrocarbon receptor belongs to the family of basic-helix–
loop–helix/Per–Arnt–Sim transcription factors. It is abundantly
expressed in numerous tissues, such as liver, lung, and placenta
(1, 2). Interestingly, AHR is highly conserved through evolution
(3), highlighting its importance across the animal kingdom. Orig-
inally, AHR was studied in the context of the biological response to
environmental toxins such as 2,3,7,8-tetrachlorodibenzo-p-dioxin
(TCDD). However, it was later found that AHR has an important
role in the regulation of immune responses by small molecules
provided by the diet, the commensal flora, and metabolism. In
its inactive state, AHR resides in the cytosol as part of a complex
that includes other proteins such as the 90 kDa heat shock protein
(HSP90), the AHR-interacting protein, p23, and the c-SRC protein
kinase (4–7). It is thought that HSP90 and p23 protect the receptor
from proteolysis and maintain a conformation suitable for ligand
binding (8).
Aryl hydrocarbon receptor is activated by ligands binding the
PAS-B domain (9), triggering a conformational change that results
in the dissociation of AHR from the chaperone proteins and the
exposure of its nuclear localization sequence (10). Ligand activa-
tion of AHR elicits genomic and non-genomic AHR-dependent
signaling pathways. Genomic AHR signaling involves the inter-
action of AHR with other transcription factors and co-activators
to directly regulate the transcription of target genes (7). After lig-
and activation, AHR translocates to the nucleus where it dimerizes
with the AHR nuclear translocator (ARNT) (11) to form an active
DNA-binding complex and control the expression of target genes
containing xenobiotic response elements (XREs) in their regula-
tory regions (9). The AHR–ARNT complex can promote or inhibit
the expression of its target genes. Moreover,ChIP-seq and microar-
ray studies with different cell types and ligands (12–14) suggest
that the AHR target genes in a specific cell are determined by the
ligands, and also the identity and developmental stage of the target
cells (15).
Non-genomic AHR signaling is more diverse and encompasses,
for example, the release of c-SRC from its complex with AHR,
resulting in the phosphorylation of c-SRC cellular targets (7). In
addition, AHR can promote the degradation of specific target pro-
teins such as estrogen and androgen receptors by the proteasome.
This ability to trigger the degradation of specific proteins results
from its E3 ligase activity, by which AHR selects proteins for ubiq-
uitination by E2 ubiquitin-conjugating enzymes. The resulting
ubiquitinated proteins are then recognized by the 26S proteasome
and degraded (16–18). Indeed, following activation AHR itself is
eventually exported out from the nucleus and degraded by the 26S
proteasome pathway (19–21).
Structure–activity relationship studies showed that AHR’s lig-
and binding pocket is promiscuous and able to accommodate
numerous hydrophobic planar compounds (22). From an his-
toric point of view, AHR can be seen as an endocrine-disrupting
chemicals (EDCs) receptor, as it is known that EDCs affect the
endocrine system either directly by AHR-dependent changes in
gene expression or indirectly via AHR cross-talk with endocrine
signaling pathways (23). However, both endogenous and exoge-
nous AHR ligands have been identified. Classical AHR ligands
include synthetic aromatic and polycyclic aromatic hydrocar-
bons (HAHs and PAHs) as well as natural ligands tetrapyrroles,
flavonoids, tryptophan derivatives, and dietary carotinoids (24).
Interestingly, some of the natural AHR ligands, such as resvera-
trol (25) and 7-ketocholestrol (26) can act as antagonists rather
than agonists. Within the endogenous AHR ligands, tryptophan-
derived metabolites have become one of the most interesting and
utmost studied group (7). It should be noted that AHR activation
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in the absence of ligand binding has also been described. Although
the relevance of this observation for vertebrates is not completely
understood, the ligand-independent activation of AHR might play
a physiological role in invertebrates (see below).
AHR EVOLUTION
Aryl hydrocarbon receptor homologs have been identified in most
major groups of animals, including the two main clades of proto-
stome invertebrates as well as deuterostomes (27, 28) highlighting
the biological importance of AHR throughout the animal king-
dom. AHR homologs identified in invertebrates share similarities
with their vertebrate counterparts, such as the interaction with
ARNT to recognize XRE (29–31). However, invertebrate AHR
homologs do not bind known AHR ligands like TCDD or β-
naphthoflavone (29, 31). Indeed, it was recently reported that the
metabolic response to xenobiotics in Caenorhabditis elegans is not
controlled by AHR (32).
In C. elegans, the orthologs of AHR and ARNT are encoded
by the AHR-related (ahr-1) and ahr-1 associated (aha-1) genes,
respectively. AHR-1 and AHA have HSP90 binding properties
comparable to those of their mammalian counterparts (31). AHR-
1 shares 38% amino acid identity with the human AHR over
the first 395 amino acids. Furthermore, AHR-1 contains a PAS
domain with both PAS-A and PAS-B repeats as well as a bHLH
domain where specific residues mediating the recognition of
mammalian XREs are conserved (31). However, AHR-1 does not
have a glutamine-rich transcriptional activation domain similar
to the one present in mammals.
Notably, mutations in AHR-1 affect several aspects of neuronal
development determining, for example, the fate of GABAergic
neurons in the L1 larval stage, regulating both cell and axon migra-
tions as well as specifying the fate of AVM light touch sensory
neuron (33–35). In addition, AHR-1 is involved in social feed-
ing (36), in which nematodes form groups on the border of the
bacterial lawn (37).
Recent studies have also demonstrated a role for AHR-1 in reg-
ulating the synthesis of long-chain unsaturated fatty acids that
eventually produce lipid signaling molecules (38). This finding is
consistent with findings in mouse models, where ligand activation
of AHR has been linked to alterations in gene expression of fatty
acid metabolism (39, 40).
The homologs of mammalian AHR and ARNT are encoded
by spineless and tango in Drosophila melanogaster (41, 42). In
agreement with observations made in C. elegans, spineless does
not bind TCDD or β-naphthoflavone (29). In addition, sequence
alignments suggest that key residues required for the interaction
of mammalian AHR with TCDD are not conserved in spineless
(29, 41). Thus, although it is still possible that the localization
and/or the activity of spineless are modified by unknown endoge-
nous ligands, it appears that this protein does not bind classical
AHR ligands functional in mammalian systems. Moreover, in cer-
tain cells spineless appears to be constitutively active (43). Spineless
plays a role in several aspects of antenna and leg development (41,
44), photoreceptor cell differentiation (45), and in controlling the
morphology of sensory neurons (46).
Not surprisingly, most of our knowledge on mammalian AHR
comes from studies on human beings and mice. Key features
characterizing mammalian AHR are (1) in contrast to other ver-
tebrates (47) all studied mammalians have a single AHR gene
and (2) AHR in mammals is not only involved in the toxic
effects of environmental pollutants (48, 49), it also has important
roles in development (50–53) and immune responses [reviewed
in Ref. (7)]. Indeed, it has been hypothesized that the original
function of the AHR might have been developmental regulation
and that AHR’s ability to bind HAHs, PAHs, and mediate adap-
tive responses involving induction of xenobiotic-metabolizing
enzymes is a vertebrate innovation (3, 47).
KYNURENINE PATHWAYS TDO/IDO AND IMMUNE
REGULATION
Tryptophan metabolites have become one of the most interest-
ing groups of endogenous AHR ligands. Especially kynurenine, an
immediate tryptophan metabolite, has been extensively studied in
recent years. The metabolic fate of tryptophan is conversion into
a range of neuroactive substances, such as serotonin and mela-
tonin. In addition, tryptophan can be catabolized into kynurenine
metabolites. Indoleamine-2,3-dioxygenase (IDO1), tryptophan-
2,3-dioxygenase (TDO), and recently discovered IDO-related
enzyme IDO2 (54) are the first and rate-limiting enzymes con-
verting tryptophan to N -formylkynurenine (55, 56) which is then
metabolized to l-kynurenine. Both TDO and IDO1 are thought
to be intracellular enzymes (57, 58). Therefore, ATP-binding cas-
sette (ABC) transporter (59), enzyme facilitating cellular entry
of tryptophan, is considered to be another rate-limiting factor in
tryptophan catabolism (60). l-Kynurenine can be catabolized by
three different ways: (1) kynurenine monooxygenase, kynuren-
inase, and 3-hydroxyanthranilic acid oxidase catalyze the syn-
thesis of anthranilic acid, 3-hydroxyanthranilic acid, quinolinic
acid, and 3-hydroxykynurenine. (2) Kynurenine aminotransfer-
eases catalyze the synthesis of kynurenic acid. (3) Kynurenine
monooxygenase and kynurenine aminotransfereases catalyze the
synthesis of xanthurenic acid (Figure 1) [reviewed in Ref. (61)].
In human beings, IDO1 is expressed in various tissues and cell
subsets following cytokine stimulation during infection, trans-
plantation, pregnancy, autoimmunity, and neoplasia (62–64).
IDO1 is constitutively expressed in many human tumors, creating
an immunosuppressive microenvironment as a result of trypto-
phan depletion and the synthesis of immunosuppressive metabo-
lites such as kynurenine (65, 66). Surprisingly, the expression of
IDO1 is controlled by AHR (67) via an autocrine AHR-IL6-STAT3
signaling loop (68). In addition, tryptophan starvation caused by
IDO1 activity, together with IDO1-dependent tryptophan catabo-
lism, inhibits the proliferation and activation of antigen-specific T
lymphocytes and induces immune tolerance (69–72). In addition,
strong evidence suggests that tryptophan catabolism can inhibit
T-cell based adaptive immunity by inducing the differentiation
of regulatory T cells (Treg) in tumors (62, 73–75). Interestingly,
kynurenine is also indicated to promote the differentiation of Tregs
(76) while suppressing antigen-specific T-cell responses (77).
In mammals, TDO2 is expressed primarily in the liver (78–80)
but can also be detected in other tissues such as the brain (79, 81–
83). TDO2 is constitutively expressed and activated in gliomas
(84). Recently, lipopolysaccharide was demonstrated to induce
TDO2 expression and via consequent production of kynurenine
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FIGURE 1 | Interplay between tryptophan metabolism andAHR.
Tryptophan is metabolized by TDO2 and IDO1 to L-kynurenine, which is further
converted to kynurenic acid. Both L-kynurenine and kynurenic acid can
activate AHR. In addition, AHR activity is influenced by environment and
therapy. Finally, AHR can activate either genomic or non-genomic
AHR-dependent signaling pathways. Red arrows indicate tryptophan
catabolism pathways, blue arrows indicate AHR activation, and black arrows
indicate pathways activated by AHR.
activate AHR-dependent pathways leading to protection against
endotoxin challenge (85). In addition, this study also reported
that endotoxin tolerance is also mediated by AHR as it was demon-
strated that AHR activation by kynurenine elicits the c-SRC depen-
dent phosphorylation of IDO1, which further regulates TGFβ1
production by dendritic cells as well as limits immunopathology
triggered by both Salmonella typhimurium and group B Strep-
tococcus (85). Furthermore, TDO2 derived kynurenine has been
demonstrated to suppress antitumor immune responses as well
as promote survival and motility of tumor cells via AHR in an
autocrine manner (84). Note that kynurenic acid can also activate
AHR signaling (86).
IDO/TDO EVOLUTION
Unfortunately, not much is know about the kynurenine pathway
in nematodes. However, the study of intestinal autofluorescence
in relation to tryptophan catabolism revealed that nematodes
having a mutated flu-1 gene show altered gut granule autofluo-
resence as well as decreased kynurenine hydroxylase activity (87).
Whereas, flu-2 mutants have reduced kynureninase and gut gran-
ule autofluorescence (87). In support of these observations, the
C. elegans genome has homologs of kynurenine hydroxylase and
kynureninase in the vicinity of flu-1 and flu-2 loci (88).
Additional putative kynurenine pathway related genes have
been identified in the C. elegans genome (89) (Figure 2). The
knock down of tdo-2, for example, abrogated the gut granule
fluorescence (90, 91). Involvement of the C. elegans kynurenine
pathway has been demonstrated in neurodegeneration and aging:
in a C. elegans model of Parkinson’s disease; RNAi knock down
of tdo-2 reduced α-synuclein aggregation-induced toxicity and
Tryptophan
N-formylkynurenine
Human
IDO
Kynurenine
3-hydroxy-
kynurenine
3-hydroxy-
anthranillic acid
kmo-1 / KMO / cinnabar
flu-2 / KYNU / ?
Kyneric acid
Xanthurenic
acid
KATII/
KATIII/
KATI
Anthranillic
acid
C.elegans D.melanogaster
tdo-2 / TDO / vermillion
afmid-1 /AFMID / CG9542
nkat-
1/nkat-
3/tatn-1
CG6950
cardinal
flu-2 / KYNU / ?
Ommochromosomes
FIGURE 2 | Schematic representation of the kynurenine pathway in
human beings (mammal), C. elegans, and D. melanogaster. Pathway tree
demonstrates differences between mammalian and invertebrate tryptophan
catabolism. Mammalian enzymes are depicted in black, C. elegans enzymes
in blue, and D. melanogaster in red. Modified from Ref. (89)
increased life span (92). However, these effects were proven to
be a result of increased tryptophan rather than changed levels of
kynurenines (92).
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In D. melanogaster, tryptophan catabolism takes place in pig-
mented eyes (93–95). Remarkably, the role of kynurenine pathway
in eye function is conserved from flies to mammals, as it plays
an essential role in protecting the lens from ultraviolet irradia-
tion (96). D. melanogaster TDO2 is encoded by vermillion. Flies
having the vermillion mutation lack brown pigment in their eyes
and have been thought to be deficient for TDO2 activity (93, 94,
97, 98). This was verified when kynurenine pathway and related
genes were described in full in 2003 (99). In the same way, as in C.
elegans, loss of vermillion function has been demonstrated to be
neuroprotective in D. melanogaster model of Huntington’s disease
(100). In addition, loss of vermillion function extend the life span
of D. melanogaster (101, 102) while resulting gradual memory
decline (103). Furthermore, white eye mutants having impaired
ABC transport show extended life spans (102). In addition, other
D. melanogaster mutants, cardinal and cinnabar, resulting in excess
of 3-hydroxykynurenine and neuroprotective kynurenic acid, have
been demonstrated to modify the brain plasticity (104).
CONCLUSION
Aryl hydrocarbon receptor, a member of the dHLH-PAS super-
family, has been identified both in invertebrates and vertebrates,
suggesting that the ancestral AHR gene arose over 500 million
years ago (3). In vertebrates, especially in mammals, the activ-
ity of AHR is mostly regulated by its interactions with ligands.
However, in invertebrates (e.g. C. elegans) AHR does not seem to
interact with TCDD or any other known ligand (105), and it is
constitutively localized in the nuclei of certain cells suggesting
ligand-independent activation (34). Similar observations have
been made for D. melanogaster´s spineless (29). Although one can-
not rule out the possibility that invertebrates require a different
kind of AHR ligands than vertebrates, it has been speculated that
in early metazoans AHR might have had a ligand-independent
roles in development. Thus, the ability of AHR to interact with lig-
ands, bind HAHs and PAHs, and regulate xenobiotic-metabolizing
enzymes has been postulated to be a vertebrate novelty (3, 47).
Aryl hydrocarbon receptor signaling modulates development
and immune function in mammals (7). Fairly recently, the involve-
ment of tryptophan metabolism has been implicated in regulating
both innate and adaptive immune responses. Most importantly,
kynurenine produced by TDO or IDO1 during tryptophan catab-
olism has been identified as an AHR ligand, linking IDO/TDO to
AHR. Considering the evolutionary conservation of the kynure-
nine pathway, it is tempting to speculate that the cross-talk between
AHR and IDO/TDO immunoregulatory pathways is a recent evo-
lutionary innovation aimed at providing a mechanism to fine tune
the immune response in response to environmental cues provided
by the tissue microenvironment. This interpretation suggests that
approaches targeting both AHR and IDO/TDO are likely to pro-
vide efficient new avenues for the therapeutic manipulation of the
immune response.
ACKNOWLEDGMENTS
This project has been supported by the National Multiple Sclerosis
Society, the National Institutes of Health, the Sigrid Juselius Foun-
dation, the Paulo Foundation, and the Finnish Multiple Sclerosis
Foundation.
REFERENCES
1. Dolwick KM, Schmidt JV, Carver LA, Swanson HI, Bradfield CA. Cloning and
expression of a human Ah receptor cDNA. Mol Pharmacol (1993) 44:911–7.
2. Dolwick KM, Swanson HI, Bradfield CA. In vitro analysis of Ah receptor
domains involved in ligand-activated DNA recognition. Proc Natl Acad Sci U S
A (1993) 90:8566–70. doi:10.1073/pnas.90.18.8566
3. Hahn ME. Aryl hydrocarbon receptors: diversity and evolution. Chem Biol
Interact (2002) 141:131–60. doi:10.1016/S0009-2797(02)00070-4
4. Kazlauskas A, Poellinger L, Pongratz I. Evidence that the co-chaperone p23 reg-
ulates ligand responsiveness of the dioxin (Aryl hydrocarbon) receptor. J Biol
Chem (1999) 274:13519–24. doi:10.1074/jbc.274.19.13519
5. Ma Q, Whitlock JP Jr. A novel cytoplasmic protein that interacts with the Ah
receptor, contains tetratricopeptide repeat motifs, and augments the transcrip-
tional response to 2,3,7,8-tetrachlorodibenzo-p-dioxin. J Biol Chem (1997)
272:8878–84. doi:10.1074/jbc.272.14.8878
6. Perdew GH. Association of the Ah receptor with the 90-kDa heat shock protein.
J Biol Chem (1988) 263:13802–5.
7. Quintana FJ, Sherr DH. Aryl hydrocarbon receptor control of adaptive immu-
nity. Pharmacol Rev (2013) 65:1148–61. doi:10.1124/pr.113.007823
8. Cox MB, Miller CA III. Cooperation of heat shock protein 90 and p23 in
aryl hydrocarbon receptor signaling. Cell Stress Chaperones (2004) 9:4–20.
doi:10.1379/460.1
9. Fukunaga BN, Probst MR, Reisz-Porszasz S, Hankinson O. Identification of
functional domains of the aryl hydrocarbon receptor. J Biol Chem (1995)
270:29270–8. doi:10.1074/jbc.270.49.29270
10. Ikuta T, Kobayashi Y, Kawajiri K. Phosphorylation of nuclear localization
signal inhibits the ligand-dependent nuclear import of aryl hydrocarbon recep-
tor. Biochem Biophys Res Commun (2004) 317:545–50. doi:10.1016/j.bbrc.2004.
03.076
11. Reyes H, Reisz-Porszasz S, Hankinson O. Identification of the Ah receptor
nuclear translocator protein (Arnt) as a component of the DNA binding
form of the Ah receptor. Science (1992) 256:1193–5. doi:10.1126/science.256.
5060.1193
12. Adachi J, Mori Y, Matsui S, Matsuda T. Comparison of gene expression pat-
terns between 2,3,7,8-tetrachlorodibenzo-p-dioxin and a natural arylhydro-
carbon receptor ligand, indirubin. Toxicol Sci (2004) 80:161–9. doi:10.1093/
toxsci/kfh129
13. Hao N, Lee KL, Furness SGB, Bosdotter C, Poellinger L, Whitelaw ML.
Xenobiotics and loss of cell adhesion drive distinct transcriptional outcomes
by aryl hydrocarbon receptor signaling. Mol Pharmacol (2012) 82:1082–93.
doi:10.1124/mol.112.078873
14. Lo R, Matthews J. High-resolution genome-wide mapping of AHR and ARNT
binding sites by ChIP-Seq. Toxicol Sci (2012) 130:349–61. doi:10.1093/toxsci/
kfs253
15. Murray IA, Morales JL, Flaveny CA, Dinatale BC, Chiaro C, Gowdahalli K, et al.
Evidence for ligand-mediated selective modulation of aryl hydrocarbon recep-
tor activity. Mol Pharmacol (2010) 77:247–54. doi:10.1124/mol.109.061788
16. Ohtake F, Fujii-Kuriyama Y, Kato S. AHR acts as an E3 ubiquitin ligase to
modulate steroid receptor functions. Biochem Pharmacol (2009) 77:474–84.
doi:10.1016/j.bcp.2008.08.034
17. Ohtake F, Baba A, Fujii-Kuriyama Y, Kato S. Intrinsic AHR function under-
lies cross-talk of dioxins with sex hormone signalings. Biochem Biophys Res
Commun (2008) 370:541–6. doi:10.1016/j.bbrc.2008.03.054
18. Ohtake F, Baba A, Takada I, Okada M, Iwasaki K, Miki H, et al. Dioxin
receptor is a ligand-dependent E3 ubiquitin ligase. Nature (2007) 446:562–6.
doi:10.1038/nature05683
19. Davarinos NA, Pollenz RS. Aryl hydrocarbon receptor imported into the
nucleus following ligand binding is rapidly degraded via the cytosplasmic
proteasome following nuclear export. J Biol Chem (1999) 274:28708–15.
doi:10.1074/jbc.274.40.28708
20. Ma Q, Baldwin KT. 2,3,7,8-tetrachlorodibenzo-p-dioxin-induced degradation
of aryl hydrocarbon receptor (AHR) by the ubiquitin-proteasome pathway.
Role of the transcription activaton and DNA binding of AHR. J Biol Chem
(2000) 275:8432–8. doi:10.1074/jbc.275.12.8432
21. Pollenz RS, Barbour ER. Analysis of the complex relationship between nuclear
export and aryl hydrocarbon receptor-mediated gene regulation. Mol Cell Biol
(2000) 20:6095–104. doi:10.1128/MCB.20.16.6095-6104.2000
22. Waller CL, McKinney JD. Three-dimensional quantitative structure-activity
relationships of dioxins and dioxin-like compounds: model validation and
Frontiers in Immunology | Immunological Tolerance October 2014 | Volume 5 | Article 521 | 4
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Jaronen and Quintana Evolution of IDO1 and AHR
Ah receptor characterization. Chem Res Toxicol (1995) 8:847–58. doi:10.1021/
tx00048a005
23. Carlson DB, Perdew GH. A dynamic role for the Ah receptor in cell signaling?
Insights from a diverse group of Ah receptor interacting proteins. J Biochem
Mol Toxicol (2002) 16:317–25. doi:10.1002/jbt.10051
24. Denison MS, Nagy SR. Activation of the aryl hydrocarbon receptor by struc-
turally diverse exogenous and endogenous chemicals. Annu Rev Pharmacol
Toxicol (2003) 43:309–34. doi:10.1146/annurev.pharmtox.43.100901.135828
25. Casper RF, Quesne M, Rogers IM, Shirota T, Jolivet A, Milgrom E, et al. Resver-
atrol has antagonist activity on the aryl hydrocarbon receptor: implications for
prevention of dioxin toxicity. Mol Pharmacol (1999) 56:784–90.
26. Savouret JF, Antenos M, Quesne M, Xu J, Milgrom E, Casper RF. 7-
ketocholesterol is an endogenous modulator for the arylhydrocarbon receptor.
J Biol Chem (2001) 276:3054–9. doi:10.1074/jbc.M005988200
27. Peterson KJ, Butterfield NJ. Origin of the Eumetazoa: testing ecological predic-
tions of molecular clocks against the Proterozoic fossil record. Proc Natl Acad
Sci U S A (2005) 102:9547–52. doi:10.1073/pnas.0503660102
28. Peterson KJ, Lyons JB, Nowak KS, Takacs CM, Wargo MJ, McPeek MA. Esti-
mating metazoan divergence times with a molecular clock. Proc Natl Acad Sci
U S A (2004) 101:6536–41. doi:10.1073/pnas.0401670101
29. Butler RA, Kelley ML, Powell WH, Hahn ME, Van Beneden RJ. An aryl hydro-
carbon receptor (AHR) homologue from the soft-shell clam, Mya arenaria:
evidence that invertebrate AHR homologues lack 2,3,7,8-tetrachlorodibenzo-
p-dioxin and beta-naphthoflavone binding. Gene (2001) 278:223–34. doi:10.
1016/S0378-1119(01)00724-7
30. Emmons RB, Duncan D, Estes PA, Kiefel P, Mosher JT, Sonnenfeld M, et al.
The spineless-aristapedia and tango bHLH-PAS proteins interact to con-
trol antennal and tarsal development in Drosophila. Development (1999)
126:3937–45.
31. Powell-Coffman JA, Bradfield CA, Wood WB. Caenorhabditis elegans orthologs
of the aryl hydrocarbon receptor and its heterodimerization partner the aryl
hydrocarbon receptor nuclear translocator. Proc Natl Acad Sci U S A (1998)
95:2844–9. doi:10.1073/pnas.95.6.2844
32. Jones LM, Rayson SJ, Flemming AJ, Urwin PE. Adaptive and specialised tran-
scriptional responses to xenobiotic stress in Caenorhabditis elegans are regu-
lated by nuclear hormone receptors. PLoS One (2013) 8:e69956. doi:10.1371/
journal.pone.0069956
33. Huang X, Powell-Coffman JA, Jin Y. The AHR-1 aryl hydrocarbon receptor and
its co-factor the AHA-1 aryl hydrocarbon receptor nuclear translocator spec-
ify GABAergic neuron cell fate in C. elegans. Development (2004) 131:819–28.
doi:10.1242/dev.00959
34. Qin H, Powell-Coffman JA. The Caenorhabditis elegans aryl hydrocarbon
receptor, AHR-1, regulates neuronal development. Dev Biol (2004) 270:64–75.
doi:10.1016/j.ydbio.2004.02.004
35. Smith CJ, O’Brien T, Chatzigeorgiou M, Spencer WC, Feingold-Link E, Hus-
son SJ, et al. Sensory neuron fates are distinguished by a transcriptional
switch that regulates dendrite branch stabilization. Neuron (2013) 79:266–80.
doi:10.1016/j.neuron.2013.05.009
36. Qin H, Zhai Z, Powell-Coffman JA. The Caenorhabditis elegans AHR-1 tran-
scription complex controls expression of soluble guanylate cyclase genes in the
URX neurons and regulates aggregation behavior. Dev Biol (2006) 298:606–15.
doi:10.1016/j.ydbio.2006.07.017
37. de Bono M, Bargmann CI. Natural variation in a neuropeptide Y receptor
homolog modifies social behavior and food response in C. elegans. Cell (1998)
94:679–89. doi:10.1016/S0092-8674(00)81609-8
38. Aarnio V, Storvik M, Lehtonen M, Asikainen S, Reisner K, Callaway J, et al. Fatty
acid composition and gene expression profiles are altered in aryl hydrocarbon
receptor-1 mutant Caenorhabditis elegans. Comp Biochem Physiol C Toxicol
Pharmacol (2010) 151:318–24. doi:10.1016/j.cbpc.2009.12.006
39. Boverhof DR, Burgoon LD, Tashiro C, Chittim B, Harkema JR, Jump DB,
et al. Temporal and dose-dependent hepatic gene expression patterns in mice
provide new insights into TCDD-Mediated hepatotoxicity. Toxicol Sci (2005)
85:1048–63. doi:10.1093/toxsci/kfi162
40. Sato S, Shirakawa H, Tomita S, Ohsaki Y, Haketa K, Tooi O, et al. Low-
dose dioxins alter gene expression related to cholesterol biosynthesis, lipo-
genesis, and glucose metabolism through the aryl hydrocarbon receptor-
mediated pathway in mouse liver. Toxicol Appl Pharmacol (2008) 229:10–9.
doi:10.1016/j.taap.2007.12.029
41. Duncan DM, Burgess EA, Duncan I. Control of distal antennal identity and
tarsal development in Drosophila by spineless-aristapedia, a homolog of the
mammalian dioxin receptor. Genes Dev (1998) 12:1290–303. doi:10.1101/gad.
12.9.1290
42. Sonnenfeld M, Ward M, Nystrom G, Mosher J, Stahl S, Crews S. The Drosophila
tango gene encodes a bHLH-PAS protein that is orthologous to mammalian
Arnt and controls CNS midline and tracheal development. Development (1997)
124:4571–82.
43. Kudo K, Takeuchi T, Murakami Y, Ebina M, Kikuchi H. Characterization
of the region of the aryl hydrocarbon receptor required for ligand depen-
dency of transactivation using chimeric receptor between Drosophila and Mus
musculus. Biochim Biophys Acta (2009) 1789:477–86. doi:10.1016/j.bbagrm.
2009.06.003
44. Struhl G. Spineless-aristapedia: a homeotic gene that does not control
the development of specific compartments in Drosophila. Genetics (1982)
102:737–49.
45. Wernet MF, Mazzoni EO, Celik A, Duncan DM, Duncan I, Desplan C. Sto-
chastic spineless expression creates the retinal mosaic for colour vision. Nature
(2006) 440:174–80. doi:10.1038/nature04615
46. Kim MD, Jan LY, Jan YN. The bHLH-PAS protein spineless is necessary for the
diversification of dendrite morphology of Drosophila dendritic arborization
neurons. Genes Dev (2006) 20:2806–19. doi:10.1101/gad.1459706
47. Hahn ME, Karchner SI, Evans BR, Franks DG, Merson RR, Lapseritis JM. Unex-
pected diversity of aryl hydrocarbon receptors in non-mammalian vertebrates:
insights from comparative genomics. J Exp Zoolog A Comp Exp Biol (2006)
305:693–706. doi:10.1002/jez.a.323
48. Fernandez-Salguero PM, Hilbert DM, Rudikoff S, Ward JM, Gonza-
lez FJ. Aryl-hydrocarbon receptor-deficient mice are resistant to 2,3,7,8-
tetrachlorodibenzo-p-dioxin-induced toxicity. Toxicol Appl Pharmacol (1996)
140:173–9. doi:10.1006/taap.1996.0210
49. Mimura J, Yamashita K, Nakamura K, Morita M, Takagi TN, Nakao K, et al.
Loss of teratogenic response to 2,3,7,8-tetrachlorodibenzo-p-dioxin (TCDD)
in mice lacking the Ah (dioxin) receptor. Genes Cells (1997) 2:645–54.
doi:10.1046/j.1365-2443.1997.1490345.x
50. Benedict JC, Lin TM, Loeffler IK, Peterson RE, Flaws JA. Physiological role of
the aryl hydrocarbon receptor in mouse ovary development. Toxicol Sci (2000)
56:382–8. doi:10.1093/toxsci/56.2.382
51. Lahvis GP, Lindell SL, Thomas RS, McCuskey RS, Murphy C, Glover E, et al.
Portosystemic shunting and persistent fetal vascular structures in aryl hydro-
carbon receptor-deficient mice. Proc Natl Acad Sci U S A (2000) 97:10442–7.
doi:10.1073/pnas.190256997
52. Robles R, Morita Y, Mann KK, Perez GI, Yang S, Matikainen T, et al. The aryl
hydrocarbon receptor, a basic helix-loop-helix transcription factor of the PAS
gene family, is required for normal ovarian germ cell dynamics in the mouse.
Endocrinology (2000) 141:450–3. doi:10.1210/endo.141.1.7374
53. Schmidt JV, Su GH, Reddy JK, Simon MC, Bradfield CA. Characterization
of a murine AHR null allele: involvement of the Ah receptor in hepatic
growth and development. Proc Natl Acad Sci U S A (1996) 93:6731–6.
doi:10.1073/pnas.93.13.6731
54. Ball HJ, Sanchez-Perez A, Weiser S, Austin CJD, Astelbauer F, Miu
J, et al. Characterization of an indoleamine 2,3-dioxygenase-like protein
found in humans and mice. Gene (2007) 396:203–13. doi:10.1016/j.gene.2007.
04.010
55. Shimizu T, Nomiyama S, Hirata F, Hayaishi O. Indoleamine 2,3-dioxygenase.
Purification and some properties. J Biol Chem (1978) 253:4700–6.
56. Takikawa O, Kuroiwa T, Yamazaki F, Kido R. Mechanism of interferon-
gamma action. Characterization of indoleamine 2,3-dioxygenase in cultured
human cells induced by interferon-gamma and evaluation of the enzyme-
mediated tryptophan degradation in its anticellular activity. J Biol Chem (1988)
263:2041–8.
57. Kudo Y, Boyd CA, Sargent IL, Redman CW. Tryptophan degradation by human
placental indoleamine 2,3-dioxygenase regulates lymphocyte proliferation.
J Physiol (2001) 535:207–15. doi:10.1111/j.1469-7793.2001.00207.x
58. Pfefferkorn ER, Rebhun S, Eckel M. Characterization of an indoleamine 2,3-
dioxygenase induced by gamma-interferon in cultured human fibroblasts.
J Interferon Res (1986) 6:267–79. doi:10.1089/jir.1986.6.267
59. Mackenzie SM, Brooker MR, Gill TR, Cox GB, Howells AJ, Ewart GD. Muta-
tions in the white gene of Drosophila melanogaster affecting ABC transporters
www.frontiersin.org October 2014 | Volume 5 | Article 521 | 5
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Jaronen and Quintana Evolution of IDO1 and AHR
that determine eye colouration. Biochim Biophys Acta (1999) 1419:173–85.
doi:10.1016/S0005-2736(99)00064-4
60. Sullivan DT, Bell LA, Paton DR, Sullivan MC. Genetic and functional analysis
of tryptophan transport in Malpighian tubules of Drosophila. Biochem Genet
(1980) 18:1109–30. doi:10.1007/BF00484342
61. Campbell BM, Charych E, Lee AW, Möller T. Kynurenines in CNS dis-
ease: regulation by inflammatory cytokines. Front Neurosci (2014) 8:12.
doi:10.3389/fnins.2014.00012
62. Curti A, Trabanelli S, Salvestrini V, Baccarani M, Lemoli RM. The role of
indoleamine 2,3-dioxygenase in the induction of immune tolerance: focus on
hematology. Blood (2009) 113:2394–401. doi:10.1182/blood-2008-07-144485
63. Liu X, Liu Y, Ding M, Wang X. Reduced expression of indoleamine 2,3-
dioxygenase participates in pathogenesis of preeclampsia via regulatory T cells.
Mol Med Rep (2011) 4:53–8. doi:10.3892/mmr.2010.395
64. Maby-El Hajjami H, Amé-Thomas P, Pangault C, Tribut O, DeVos J, Jean R,
et al. Functional alteration of the lymphoma stromal cell niche by the cytokine
context: role of indoleamine-2,3 dioxygenase. Cancer Res (2009) 69:3228–37.
doi:10.1158/0008-5472.CAN-08-3000
65. Munn DH, Mellor AL. Indoleamine 2,3-dioxygenase and tumor-induced tol-
erance. J Clin Invest (2007) 117:1147–54. doi:10.1172/JCI31178
66. Platten M, Wick W, Van den Eynde BJ. Tryptophan catabolism in can-
cer: beyond IDO and tryptophan depletion. Cancer Res (2012) 72:5435–40.
doi:10.1158/0008-5472.CAN-12-0569
67. Vogel CFA, Goth SR, Dong B, Pessah IN, Matsumura F. Aryl hydrocarbon recep-
tor signaling mediates expression of indoleamine 2,3-dioxygenase. Biochem
Biophys Res Commun (2008) 375:331–5. doi:10.1016/j.bbrc.2008.07.156
68. Litzenburger UM, Opitz CA, Sahm F, Rauschenbach KJ, Trump S, Winter
M, et al. Constitutive IDO expression in human cancer is sustained by an
autocrine signaling loop involving IL-6, STAT3 and the AHR. Oncotarget
(2014) 5:1038–51.
69. Frumento G, Rotondo R, Tonetti M, Damonte G, Benatti U, Ferrara GB.
Tryptophan-derived catabolites are responsible for inhibition of T and nat-
ural killer cell proliferation induced by indoleamine 2,3-dioxygenase. J Exp
Med (2002) 196:459–68. doi:10.1084/jem.20020121
70. Grohmann U, Fallarino F, Puccetti P. Tolerance, DCs and tryptophan: much ado
about IDO. Trends Immunol (2003) 24:242–8. doi:10.1016/S1471-4906(03)
00072-3
71. Mellor AL, Keskin DB, Johnson T, Chandler P, Munn DH. Cells express-
ing indoleamine 2,3-dioxygenase inhibit T cell responses. J Immunol (2002)
1950(168):3771–6. doi:10.4049/jimmunol.168.8.3771
72. Sznurkowski JJ, Zawrocki A, Emerich J, Sznurkowska K, Biernat W. Expres-
sion of indoleamine 2,3-dioxygenase predicts shorter survival in patients with
vulvar squamous cell carcinoma (vSCC) not influencing on the recruitment
of FOXP3-expressing regulatory T cells in cancer nests. Gynecol Oncol (2011)
122:307–12. doi:10.1016/j.ygyno.2011.04.050
73. Curti A, Trabanelli S, Onofri C, Aluigi M, Salvestrini V, Ocadlikova
D, et al. Indoleamine 2,3-dioxygenase-expressing leukemic dendritic cells
impair a leukemia-specific immune response by inducing potent T regu-
latory cells. Haematologica (2010) 95:2022–30. doi:10.3324/haematol.2010.
025924
74. Curti A, Pandolfi S, Valzasina B, Aluigi M, Isidori A, Ferri E, et al. Modula-
tion of tryptophan catabolism by human leukemic cells results in the con-
version of CD25- into CD25+ T regulatory cells. Blood (2007) 109:2871–7.
doi:10.1182/blood-2006-07-036863
75. Levina V, Su Y, Gorelik E. Immunological and nonimmunological effects of
indoleamine 2,3-dioxygenase on breast tumor growth and spontaneous metas-
tasis formation. Clin Dev Immunol (2012) 2012:173029. doi:10.1155/2012/
173029
76. Mezrich JD, Fechner JH, Zhang X, Johnson BP, Burlingham WJ, Bradfield
CA. An interaction between kynurenine and the aryl hydrocarbon recep-
tor can generate regulatory T cells. J Immunol (2010) 1950(185):3190–8.
doi:10.4049/jimmunol.0903670
77. Platten M, Ho PP, Youssef S, Fontoura P, Garren H, Hur EM, et al. Treatment
of autoimmune neuroinflammation with a synthetic tryptophan metabolite.
Science (2005) 310:850–5. doi:10.1126/science.1117634
78. Britan A, Maffre V, Tone S, Drevet JR. Quantitative and spatial differences in
the expression of tryptophan-metabolizing enzymes in mouse epididymis. Cell
Tissue Res (2006) 324:301–10. doi:10.1007/s00441-005-0151-7
79. Haber R, Bessette D, Hulihan-Giblin B, Durcan MJ, Goldman D. Identifica-
tion of tryptophan 2,3-dioxygenase RNA in rodent brain. J Neurochem (1993)
60:1159–62. doi:10.1111/j.1471-4159.1993.tb03269.x
80. Yuasa HJ, Takubo M, Takahashi A, Hasegawa T, Noma H, Suzuki T. Evolu-
tion of vertebrate indoleamine 2,3-dioxygenases. J Mol Evol (2007) 65:705–14.
doi:10.1007/s00239-007-9049-1
81. Miller CL, Llenos IC, Dulay JR, Barillo MM, Yolken RH, Weis S. Expression
of the kynurenine pathway enzyme tryptophan 2,3-dioxygenase is increased
in the frontal cortex of individuals with schizophrenia. Neurobiol Dis (2004)
15:618–29. doi:10.1016/j.nbd.2003.12.015
82. Minatogawa Y, Suzuki S, Ando Y, Tone S, Takikawa O. Tryptophan pyrrole
ring cleavage enzymes in placenta. Adv Exp Med Biol (2003) 527:425–34.
doi:10.1007/978-1-4615-0135-0_50
83. Suzuki S, Toné S, Takikawa O, Kubo T, Kohno I, Minatogawa Y.
Expression of indoleamine 2,3-dioxygenase and tryptophan 2,3-dioxygenase
in early concepti. Biochem J (2001) 355:425–9. doi:10.1042/0264-6021:
3550425
84. Opitz CA, Litzenburger UM, Sahm F, Ott M, Tritschler I, Trump S, et al. An
endogenous tumour-promoting ligand of the human aryl hydrocarbon recep-
tor. Nature (2011) 478:197–203. doi:10.1038/nature10491
85. Bessede A, Gargaro M, Pallotta MT, Matino D, Servillo G, Brunacci C, et al. Aryl
hydrocarbon receptor control of a disease tolerance defence pathway. Nature
(2014) 511:184–90. doi:10.1038/nature13323
86. DiNatale BC, Murray IA, Schroeder JC, Flaveny CA, Lahoti TS, Lauren-
zana EM, et al. Kynurenic acid is a potent endogenous aryl hydrocarbon
receptor ligand that synergistically induces interleukin-6 in the presence of
inflammatory signaling. Toxicol Sci (2010) 115:89–97. doi:10.1093/toxsci/
kfq024
87. Siddiqui SS, Babu P. Kynurenine hydroxylase mutants of the nema-
tode Caenorhabditis elegans. Mol Gen Genet (1980) 179:21–4. doi:10.1007/
BF00268441
88. Altschul SF, Gish W, Miller W, Myers EW, Lipman DJ. Basic local align-
ment search tool. J Mol Biol (1990) 215:403–10. doi:10.1016/S0022-2836(05)
80360-2
89. Van der Goot AT, Nollen EAA. Tryptophan metabolism: entering the field
of aging and age-related pathologies. Trends Mol Med (2013) 19:336–44.
doi:10.1016/j.molmed.2013.02.007
90. Coburn C, Allman E, Mahanti P, Benedetto A, Cabreiro F, Pincus Z, et al.
Anthranilate fluorescence marks a calcium-propagated necrotic wave that
promotes organismal death in C. elegans. PLoS Biol (2013) 11:e1001613.
doi:10.1371/journal.pbio.1001613
91. Coburn C, Gems D. The mysterious case of the C. elegans gut granule: death
fluorescence, anthranilic acid and the kynurenine pathway. Front Genet (2013)
4:151. doi:10.3389/fgene.2013.00151
92. Van der Goot AT, Zhu W, Vázquez-Manrique RP, Seinstra RI, Dettmer K,
Michels H, et al. Delaying aging and the aging-associated decline in protein
homeostasis by inhibition of tryptophan degradation. Proc Natl Acad Sci U S
A (2012) 109:14912–7. doi:10.1073/pnas.1203083109
93. Baillie DL, Chovnick A. Studies on the genetic control of tryptophan pyrrolase
in Drosophila melanogaster. Mol Gen Genet (1971) 112:341–53. doi:10.1007/
BF00334435
94. Tartof KD. Interacting gene systems: I. the regulation of tryptophan pyrrolase
by the vermilion-suppressor of vermilion system in Drosophila. Genetics (1969)
62:781–95.
95. Tearle R. Tissue specific effects of ommochrome pathway mutations
in Drosophila melanogaster. Genet Res (1991) 57:257–66. doi:10.1017/
S0016672300029402
96. Roberts JE. Ocular phototoxicity. J Photochem Photobiol B (2001) 64:136–43.
doi:10.1016/S1011-1344(01)00196-8
97. Beadle GW, Ephrussi B. Development of eye colors in Drosophila: transplanta-
tion experiments with suppressor of vermilion. Proc Natl Acad Sci U S A (1936)
22:536–40. doi:10.1073/pnas.22.9.536
98. Searles LL, Voelker RA. Molecular characterization of the Drosophila vermilion
locus and its suppressible alleles. Proc Natl Acad Sci U S A (1986) 83:404–8.
doi:10.1073/pnas.83.2.404
99. Savvateeva-Popova EV, Popov AV, Heinemann T, Riederer P. Drosophila
mutants of the kynurenine pathway as a model for ageing studies. Adv Exp
Med Biol (2003) 527:713–22. doi:10.1007/978-1-4615-0135-0_84
Frontiers in Immunology | Immunological Tolerance October 2014 | Volume 5 | Article 521 | 6
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Jaronen and Quintana Evolution of IDO1 and AHR
100. Campesan S, Green EW, Breda C, Sathyasaikumar KV, Muchowski PJ, Schwarcz
R, et al. The kynurenine pathway modulates neurodegeneration in a Drosophila
model of Huntington’s disease. Curr Biol (2011) 21:961–6. doi:10.1016/j.cub.
2011.04.028
101. Oxenkrug GF. The extended life span of Drosophila melanogaster eye-color
(white and vermilion) mutants with impaired formation of kynurenine.
J Neural Transm (2010) 1996(117):23–6. doi:10.1007/s00702-009-0341-7
102. Oxenkrug GF, Navrotskaya V, Voroboyva L, Summergrad P. Extension of life
span of Drosophila melanogaster by the inhibitors of tryptophan-kynurenine
metabolism. Fly (Austin) (2011) 5:307–9. doi:10.4161/fly.5.4.18414
103. Savvateeva EV, Popov AV, Kamyshev NG, Iliadi KG, Bragina JV, Heisen-
berg M, et al. Age-dependent changes in memory and mushroom bod-
ies in the Drosophila mutant vermilion deficient in the kynurenine path-
way of tryptophan metabolism. Ross Fiziol Zh Im I M Sechenova (1999)
85:167–83.
104. Savvateeva E, Popov A, Kamyshev N, Bragina J, Heisenberg M, Senitz
D, et al. Age-dependent memory loss, synaptic pathology and altered
brain plasticity in the Drosophila mutant cardinal accumulating 3-
hydroxykynurenine. J Neural Transm (2000) 1996(107):581–601. doi:10.1007/
s007020070080
105. Powell-Coffman JA, Qin H. Invertebrate AHR homologs: ancestral functions
in sensory systems. In: Pohjanvirta R, editor. The AH Receptor in Biology and
Toxicology. Hoboken, NJ: John Wiley & Sons, Inc (2011). p. 405–11.
Conflict of Interest Statement: The authors declare that the research was conducted
in the absence of any commercial or financial relationships that could be construed
as a potential conflict of interest.
Received: 10 September 2014; accepted: 06 October 2014; published online: 20 October
2014.
Citation: Jaronen M and Quintana FJ (2014) Immunological relevance of the coevo-
lution of IDO1 and AHR. Front. Immunol. 5:521. doi: 10.3389/fimmu.2014.00521
This article was submitted to Immunological Tolerance, a section of the journal Frontiers
in Immunology.
Copyright © 2014 Jaronen and Quintana. This is an open-access article distributed
under the terms of the Creative Commons Attribution License (CC BY). The use, dis-
tribution or reproduction in other forums is permitted, provided the original author(s)
or licensor are credited and that the original publication in this journal is cited, in
accordance with accepted academic practice. No use, distribution or reproduction is
permitted which does not comply with these terms.
www.frontiersin.org October 2014 | Volume 5 | Article 521 | 7
